Advanced keratinocyte skin cancer is a tumor with considerable disease burden and aggressiveness
- PDF / 525,352 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 80 Downloads / 170 Views
LETTER TO THE EDITOR
Advanced keratinocyte skin cancer is a tumor with considerable disease burden and aggressiveness Ioannis D. Bassukas1 · Konstantinos K. Tsilidis2,3 · Panagiota Spyridonos4 Received: 7 August 2019 / Revised: 22 July 2020 / Accepted: 12 September 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract In a 2013 study published in this Journal, Dacosta Byfield et al. used MediCare data to extract reliable estimations of the incidence (I = 6.16) and prevalence (P = 10.31) rates of advanced keratinocyte skin cancer (aKSC) per 100,000 US population. These data unmask a considerable disease burden of aKSC (tumor stages ≥ 3) compared to the corresponding projected SEER predictions in 2019 of all invasive cases (tumor stages ≥ 1). According to its incidence, aKSC ranks 19th out of 29 major SEER registered neoplasms and has an average disease duration of 1.67 years, which is the second shortest disease duration next only to pancreatic carcinoma. Furthermore, in support of the high disease aggressiveness of aKSC and using a calibration approach, we calculated a mortality estimate of 4.64 per 100,000 and a 5-year survival rate of 21.8% for this tumor, which corresponds to positions of 13th and 5th out of 29 cancers among the SEER tracked malignancies, respectively. Taken together, these data indicate a considerable disease burden and biologic aggressiveness of aKSC. Keywords Advanced keratinocyte skin cancer · Incidence · Prevalence · Mortality · 5-year survival rate · Basal cell carcinoma · Cutaneous squamous cell carcinoma In a study published in 2013 in this Journal, Dacosta Byfield et al. employed the records from a large private insurance database (Optum Research Database) to estimate the incidence and prevalence of advanced Keratinocyte Skin Cancer (aKSC) in 2010 in the USA [1]. They reported 19,031 newly diagnosed aKSC cases and 31,834 patients living with aKSC, which correspond to incidence (I) and prevalence (P) rates of 6.16 and 10.31 per 100,000 US population. The comparison of these latter epidemiological data for aKSC This comment refers to the article available online at https://doi. org/10.1007/s00403-013-1357-2. * Ioannis D. Bassukas [email protected] 1
Department of Skin and Venereal Diseases, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
2
Department of Hygiene and Epidemiology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
3
Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
4
Department of Medical Physics, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
with data from the SEER database in 2019 on projected corresponding estimations for the tracked malignancies [2] (Table 1) unmasks the relatively high disease burden of aKSC (exclusively tumor stages ≥ 3), even when compared to the cases of all invasive stages of other neoplasms (tumor stages ≥ 1) as reported by SEER.
Data Loading...
